Human Papillomavirus Vaccine Initiation and Awareness

U.S. Young Men in the 2010 National Health Interview Survey


      In 2009, the quadrivalent human papillomavirus (HPV) vaccine was licensed by the U.S. Food and Drug Administration for use in men/boys aged 9–26 years. In 2009, the Advisory Committee on Immunization Practices (ACIP) provided a permissive recommendation allowing HPV vaccine administration to this group.


      To assess HPV vaccination initiation and coverage, evaluate awareness of HPV and HPV vaccine, and identify factors independently associated with such awareness among men aged 18–26 years.


      Data from the 2010 National Health Interview Survey were analyzed in 2011.


      In 2010, HPV vaccination initiation among men aged 18–26 years was 1.1%. Among the 1741 men interviewed in this age group, nearly half had heard of HPV (51.8%). Overall, about one third of these men had heard of the HPV vaccine (34.8%). Factors independently associated with a higher likelihood of awareness of both HPV and HPV vaccine among men aged 18–26 years included having non-Hispanic white race/ethnicity; a higher education level; a U.S. birthplace; more physician contacts; private health insurance; received other vaccines; and reported risk behaviors related to sexually transmitted diseases, including HIV.


      HPV vaccination initiation among men aged 18–26 years in 2010 was low. HPV and HPV vaccine awareness were also low, and messages in this area directed to men are needed. Since ACIP published a recommendation for routine use of HPV4 among men/boys in December 2011, continued monitoring of HPV vaccination uptake among men aged 18–26 years is useful for evaluating the vaccination campaigns, and planning and implementing strategies to increase coverage.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Preventive Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • CDC
        Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
        MMWR Recomm Rep. 2007; 56: 1-24
        • Schiffman M.
        • Kjaer S.K.
        Natural history of anogenital human papillomavirus infection and neoplasia.
        J Natl Cancer Inst Monogr. 2003; 31: 14-19
        • Koutsky L.
        Epidemiology of genital human papillomavirus infection.
        Am J Med. 1997; 102: 3-8
        • CDC
        Recommendations on the use of quadrivalent human papillomavirus vaccine in males—Advisory Committee on Immunization Practices (ACIP), 2011.
        MMWR Morb Mortal Wkly Rep. 2011; 60: 1705-1708
        • Joseph D.A.
        • Miller J.W.
        • Wu X.
        • et al.
        Understanding the burden of human papillomavirus-associated anal cancers in the U.S..
        Cancer. 2008; 113: 2892-2900
        • Gillison M.L.
        • Chaturvedi A.K.
        • Lowy D.R.
        HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women.
        Cancer. 2008; 113: 3036-3046
        • Chaturvedi A.K.
        • Engels E.A.
        • Pfeiffer R.M.
        • et al.
        Human papillomavirus and rising oropharyngeal cancer incidence in the U.S..
        J Clin Oncol. 2011; 29: 4294-4301
        • Saraiya M.
        Burden of HPV-associated cancers in the U.S. Presentation before the Advisory Committee on Immunization Practices (ACIP), February 24, 2011.
        DHHS, CDC, Atlanta GA2011
        • Hu D.
        • Goldie S.
        The economic burden of noncervical human papillomavirus disease in the U.S..
        Am J Obstet Gynecol. 2008; 198: 500-507
        • Hoy T.
        • Singhal P.K.
        • Willey V.J.
        • Insinga R.P.
        Assessing incidence and economic burden of genital warts with data from a U.S. commercially insured population.
        Curr Med Res Opin. 2009; 25: 2343-2351
        • CDC
        The Advisory Committee on Immunization Practices (ACIP): summary report, October 27−28, 2010, Atlanta GA.
        • CDC
        FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP).
        MMWR Morb Mortal Wkly Rep. 2010; 59: 630-632
        • Gutierrez Jr, B.
        • Leung A.
        • Jones K.T.
        • et al.
        Acceptability of the human papillomavirus vaccine among urban adolescent males.
        Am J Mens Health. 2013; 7: 27-36
        • Reiter P.L.
        • McRee A.L.
        • Kadis J.A.
        • Brewer N.T.
        HPV vaccine and adolescent males.
        Vaccine. 2011; 29: 5595-5602
        • CDC
        National Health Interview Survey.
        • Jain N.
        • Euler G.L.
        • Shefer A.
        • Lu P.
        • Yankey D.
        • Markowitz L.
        Human papillomavirus (HPV) awareness and vaccination initiation among women in the U.S., National Immunization Survey-Adult 2007.
        Prev Med. 2009; 48: 426-431
        • Medeiros R.
        • Ramada D.
        Knowledge differences between male and female university students about human papillomavirus (HPV) and cervical cancer: implications for health strategies and vaccination.
        Vaccine. 2010; 29 (16): 153-160
        • Marek E.
        • Dergez T.
        • Rebek-Nagy G.
        • et al.
        Adolescents' awareness of HPV infections and attitudes towards HPV vaccination 3 years following the introduction of the HPV vaccine in Hungary.
        Vaccine. 2011; 29: 8591-8598
      1. Pitching protection, to both mothers and daughters.
        • Oh J.K.
        • Lim M.K.
        • Yun E.H.
        • Lee E.H.
        • Shin H.R.
        Awareness of and attitude towards human papillomavirus infection and vaccination for cervical cancer prevention among adult males and females in Korea: a nationwide interview survey.
        Vaccine. 2010; 28: 1854-1860
        • Tiro J.A.
        • Meissner H.I.
        • Kobrin S.
        • Chollette V.
        What do women in the U.S. know about human papillomavirus and cervical cancer?.
        Cancer Epidemiol. 2007; 16: 288-294
        • CDC
        Education & training: 2012 epidemiology & prevention of vaccine-preventable diseases.
        • CDC
        Education & training: vaccine-preventable diseases: HPV vaccination.
      2. HPV vaccine now recommended for boys and young men.
      3. HPV4 vaccine information statement.
      4. HPV vaccines offer disease protection pre-teens can grow into—now for girls and boys.
        • Callahan S.T.
        • Cooper W.O.
        Gender and uninsurance among young adults in the U.S..
        Pediatrics. 2004; 113: 291-297
        • Sherris J.
        • Friedman A.
        • Wittet S.
        • Davies P.
        • Steben M.
        • Saraiya M.
        Chapter 25: Education, training, and communication for HPV vaccines.
        Vaccine. 2006; 24: S210-S218
        • Cui Y.
        • Baldwin S.B.
        • Wiley D.J.
        • Fielding J.E.
        Human papillomavirus vaccine among adult women: disparities in awareness and acceptance.
        Am J Prev Med. 2010; 39: 559-563
        • Niccolai L.M.
        • Mehta N.R.
        • Hadler J.L.
        Racial/ethnic and poverty disparities in human papillomavirus vaccination completion.
        Am J Prev Med. 2011; 41: 428-433
        • Liddon N.C.
        • Leichliter J.S.
        • Markowitz L.E.
        Human papillomavirus vaccine and sexual behavior among adolescent and young women.
        Am J Prev Med. 2012; 42: 44-52
        • Reiter P.L.
        • Brewer N.T.
        • Gottlieb S.L.
        • McRee A.L.
        • Smith J.S.
        Parents' health beliefs and HPV vaccination of their adolescent daughters.
        Soc Sci Med. 2009; 69: 475-480
        • Brewer N.T.
        • Fazekas K.I.
        Predictors of HPV vaccine acceptability: a theory informed, systematic review.
        Prev Med. 2007; 45: 107-114
        • Hughes J.
        • Cates J.R.
        • Liddon N.
        • Smith J.S.
        • Gottlieb S.L.
        • Brewer N.T.
        Disparities in how parents are learning about the human papillomavirus vaccine.
        Cancer Epidemiol Biomarkers Prev. 2009; 18: 363-372
        • Briss P.A.
        • Rodewald L.E.
        • Hinman A.R.
        • et al.
        Reviews of evidence regarding interventions to improve vaccination coverage in children, adolescents, and adults.
        Am J Prev Med. 2000; 18: 97-140
        • Tierney C.D.
        • Yusuf H.
        • McMahon S.R.
        • et al.
        Adoption of reminder and recall messages for immunizations by pediatricians and public health clinics.
        Pediatrics. 2003; 112: 1076-1082
        • Anhang Price R.
        • Tiro J.A.
        • Saraiya M.
        • Meissner H.
        • Breen N.
        Use of human papillomavirus vaccines among young adult women in the U.S.: an analysis of the 2008 National Health Interview Survey.
        Cancer. 2011; 117: 5560-5568
        • Miller B.L.
        • Kretsinger K.
        • Euler G.L.
        • Lu P.J.
        • Ahmed F.
        Barriers to early uptake of tetanus, diphtheria and acellular pertussis vaccine (Tdap) among adults—U.S., 2005–2007.
        Vaccine. 2011; 29: 3850-3856
        • Lu P.J.
        • Euler G.L.
        • Hennessey K.A.
        • Weinbaum C.M.
        Hepatitis A vaccination coverage among adults aged 18-49 years in the U.S..
        Vaccine. 2009; 27: 1301-1305
        • Bednarczyk R.A.
        • Birkhead G.S.
        • Morse D.L.
        • Doleyres H.
        • McNutt L.A.
        Human papillomavirus vaccine uptake and barriers: association with perceived risk, actual risk and race/ethnicity among female students at a New York State university, 2010.
        Vaccine. 2011; 29: 3138-3143
        • Taylor L.D.
        • Hariri S.
        • Sternberg M.
        • Dunne E.F.
        • Markowitz L.E.
        Human papillomavirus vaccine coverage in the U.S., National Health and Nutrition Examination Survey, 2007–2008.
        Prev Med. 2011; 52: 398-400
        • Stokley S.
        • Cohn A.
        • Dorell C.
        • et al.
        Adolescent vaccination-coverage levels in the U.S.: 2006−2009.
        Pediatrics. 2011; 128: 1078-1086
        • Egede L.E.
        • Zheng D.
        Racial/ethnic differences in adult vaccination among individuals with diabetes.
        Am J Public Health. 2003; 93: 324-329
        • Smith P.J.
        • Stevenson J.
        • Chu S.Y.
        Associations between childhood vaccination coverage, insurance type, and breaks in health insurance coverage.
        Pediatrics. 2006; 117: 1972-1978
        • Kempe A.
        • Beaty B.
        • Englund B.P.
        • Roark R.J.
        • Hester N.
        • Steiner J.F.
        Quality of care and use of the medical home in a state-funded capitated primary care plan for low-income children.
        Pediatrics. 2000; 105: 1020-1028
        • Holl J.L.
        • Szilagyi P.G.
        • Rodewald L.E.
        • et al.
        Evaluation of New York State's Child Health Plus: access, utilization, quality of health care, and health status.
        Pediatrics. 2000; 105: 711-718
        • Dombkowski K.J.
        • Lantz P.M.
        • Freed G.L.
        Role of health insurance and a usual source of medical care in age-appropriate vaccination.
        Am J Public Health. 2004; 94: 960-966
      5. Merck Vaccine Patient Assistance Program.
        • CDC
        Immunization Grant Program (Section 317).
        • CDC
        Adult vaccination coverage, U.S., 2010.
        MMWR Morb Mortal Wkly Rep. 2012; 61: 66-72
      6. The Affordable Care Act.
        • Donald R.M.
        • Baken L.
        • Nelson A.
        • Nichol K.L.
        Validation of self-report of influenza and pneumococcal vaccination status in elderly outpatients.
        Am J Prev Med. 1999; 16: 173-177
        • Shenson D.
        • Dimartino D.
        • Bolen J.
        • Campbell M.
        • Lu P.J.
        • Singleton J.A.
        Validation of self-reported pneumococcal vaccination in behavioral risk factor surveillance surveys: experience from the sickness prevention achieved through regional collaboration (SPARC) program.
        Vaccine. 2005; 23: 1015-1020
        • Dorell C.G.
        • Jain N.
        • Yankey D.
        Validity of parent-reported vaccination status for adolescents aged 13-17 years: National Immunization Survey-Teen, 2008.
        Public Health Rep. 2011; 126: 60-69
        • Poland G.A.
        • Shefer A.M.
        • McCauley M.
        • et al.
        Standards for adult immunization practice.
        Am J Prev Med. 2003; 25: 144-150